Is antiphospholipid syndrome an autoimmune disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Is Antiphospholipid Syndrome Autoimmune?

Yes, antiphospholipid syndrome (APS) is definitively an autoimmune disease characterized by the production of autoantibodies (antiphospholipid antibodies) that target phospholipids and phospholipid-binding proteins, leading to thrombosis, pregnancy complications, and other inflammatory manifestations.

Disease Classification

APS is classified as a systemic autoimmune disorder that can present in two forms 1, 2, 3:

  • Primary APS: Occurs as an isolated autoimmune condition
  • Secondary APS: Develops in association with other autoimmune diseases, most commonly systemic lupus erythematosus (SLE)

The autoimmune nature is evident from the fact that patients with aPS/PT positivity show higher prevalence of APS associated with other autoimmune diseases compared to primary APS, supporting the link to autoimmune pathophysiology 1.

Autoimmune Mechanism

The disease is driven by autoantibodies that recognize phospholipid surfaces and phospholipid-binding proteins 1. The major autoantibodies responsible include:

  • Lupus anticoagulant (LA)
  • Anticardiolipin antibodies (aCL)
  • Anti-β2-glycoprotein I antibodies (aβ2GPI)
  • Antiprothrombin antibodies 1

These autoantibodies induce a thrombo-inflammatory disease process by interfering with coagulation, causing endothelial damage, activating platelets, and triggering inflammatory signaling pathways 3, 4.

Clinical Significance

The autoimmune classification is critical because:

  • It explains the association with other autoimmune conditions, particularly SLE 1
  • It guides treatment approaches that may include immunomodulatory therapies in addition to anticoagulation 4
  • It necessitates monitoring for development of additional autoimmune manifestations
  • The presence of persistent autoantibodies is mandatory for diagnosis, distinguishing it from transient antibody production 5

The 2023 ACR/EULAR classification criteria explicitly recognize APS as an autoimmune syndrome, incorporating both the autoantibody profile and clinical manifestations into a weighted scoring system 2, 6.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.